News and Information-Learn About Hepatitis, Liver Cirrhosis, and Others
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Drug Shows Promise Against Childhood Epilepsy

Rapamycin helped suppress seizures in mouse study

MONDAY, June 15 (HealthDay News) -- A drug commonly used to prevent rejection in organ transplant patients may be effective against childhood epilepsy, animal studies suggest.

The drug, rapamycin (also known as sirolimus), appears to block seizures in mice with cortical dysplasia, a brain malformation that is a common cause of childhood epilepsy and a frequent reason for pediatric epilepsy surgery, said Gabriella D'Arcangelo, an associate professor in the department of cell biology and neuroscience at Rutgers, the State University of New Jersey.

Advertisement
Related Stories
 border=
Kidney Donors Go On to Lead Long, Healthy Lives
1 in 5 At-Risk U.S. Babies Doesn't Get Hepatitis B Vaccine
Early Liver Detection Methods Ineffective
Related Videos
 border=
Blood Cleaner
High Tech Liver Surgery
Living Longer With Liver Cancer
Related Slides
 border=
Hepatitis
Liver Cirrhosis
Liver Transplant
Related Encyclopedia
 border=
Arteriohepatic Dysplasia
Fatty Liver
Hemochromatosis


"The surgery is not without risks, and while it may help control the seizures, it does not work in all cases," D'Arcangelo said in a news release from the university. "Clearly, there is a pressing need to come up with new strategies for treatment."

In the study, published online in the journal Disease Models and Mechanisms, researchers tested rapamycin, a widely available immunosuppressive, on mice bred to display traits of cortical dysplasia.

"We demonstrated that rapamycin is a novel and effective anti-epileptic agent that suppresses seizures in our mice," D'Arcangelo stated. "And this has raised some hope for the future."

Human trials have not begun; however, patients with tuberous sclerosis, a subtype of cortical dysplasia that causes benign tumors to grow in the brain and other vital organs, are currently taking the drug in a multi-center study in the United States, D'Arcangelo noted in the news release.

Epilepsy, along with stroke and Alzheimer's, is one of the most common neurological diseases in the United States, affecting an estimated 3 million people. More than 326,000 children under the age of 15 have the disorder, and nearly one-third of them do not respond adequately to treatment.

Symptoms include seizures that can last from a few seconds to several minutes and may involve loss of consciousness, according to the Epilepsy Foundation. Uncontrolled seizures and heavy medications in children often lead to cognitive problems.

More information

To learn more about epilepsy, visit the Epilepsy Foundation.

-- Peter West

SOURCE: Rutgers University, news release, June 10, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 6/15/2009



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Mar 11, 2010
Home
Search
Powered By HealthLine
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: